Search research articles
Contact Us
Filters
Showing results (51-60 of 98) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Mark Kirschbaum, Paul Frankel, Leslie Popplewell, et al.
Cancers
|
November 27, 2021
Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides
Cosimo Di Raimondo, Zhen Han, Chingyu Su, et al.
Blood
|
April 19, 2012
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
Ajay K Gopal, Radhakrishnan Ramchandren, Owen A O'Connor, et al.
JCI Insight
|
July 10, 2023
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma
Zhen Han, Xiwei Wu, Hanjun Qin, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Blood Advances
|
February 14, 2025
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma
Christiane Querfeld, Joycelynne Palmer, Zhen Han, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 12, 2018
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
Badri Modi, Michael Hernandez-Henderson, Dongyun Yang, et al.
Cancers
|
August 23, 2020
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M Haverkos, Jasmine Zain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Haematologica
|
July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial
Geoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 98) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Mark Kirschbaum, Paul Frankel, Leslie Popplewell, et al.
Cancers
|
November 27, 2021
Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides
Cosimo Di Raimondo, Zhen Han, Chingyu Su, et al.
Blood
|
April 19, 2012
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
Ajay K Gopal, Radhakrishnan Ramchandren, Owen A O'Connor, et al.
JCI Insight
|
July 10, 2023
Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma
Zhen Han, Xiwei Wu, Hanjun Qin, et al.
Leukemia & Lymphoma
|
December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Ajay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Blood Advances
|
February 14, 2025
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma
Christiane Querfeld, Joycelynne Palmer, Zhen Han, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 12, 2018
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease
Badri Modi, Michael Hernandez-Henderson, Dongyun Yang, et al.
Cancers
|
August 23, 2020
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M Haverkos, Jasmine Zain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Haematologica
|
July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial
Geoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Page
of 10